The company that turned a $6,000 diabetes gadget into a $249 ring

In the medical-device business, the easy money sits at the top. Build a fancier sensor, price it high, sell it to the patients and hospitals that can afford it, repeat. Piyush Gupta spent years inside Abbott, one of the companies that plays that game well. Then he left to build the opposite thing.

Ambrosia Systems, the San Francisco company Gupta founded in 2016, has a mission you can fit on a business card: make continuous glucose monitoring cheap enough that anyone, anywhere, can use it. Not a better number. A reachable one. The company's own framing of the challenge is blunt.

That single idea explains almost everything Ambrosia has shipped - a clip-on transmitter, a phone-free Apple Watch feed, a global subscription service, and, most recently, a titanium ring called RIZZ that estimates your glucose trends without ever breaking skin. It also explains a number the company likes to repeat: it says it has driven the cost of continuous monitoring down from roughly $6,000 to $2,000 per patient, and it is aiming at under $100 a year.

01 / What they actually doTurning a scan-patch into a live monitor

Start with the problem. Abbott's FreeStyle Libre is one of the most popular glucose sensors on earth, a small patch worn on the arm. But in its base form it is a flash monitor: you have to physically wave a phone or reader over it to get a reading. Miss a scan overnight and you miss the data.

Ambrosia's first product, the NightRider BluCon, solves that with a tiny device that clips over the Libre patch, reads its NFC signal automatically every five minutes, and beams the number over Bluetooth to a phone - or straight to a watch. A flash patch becomes a real-time continuous glucose monitor. The companion apps, LinkBluCon and FollowBluCon, add alarms for highs, lows, and fast swings, and let up to five caregivers follow a patient remotely. There is even an Amazon Alexa skill, so a parent can ask a smart speaker for a child's glucose level out loud.

In 2019 Ambrosia added the feature it is proudest of: glucose on an Apple Watch without a paired iPhone nearby. The reason is less about gadget flexing and more about who actually wears these things.

02 / The price storyGoing down-market on purpose

Most health startups pitch upward. Ambrosia pointed the other way, toward what StartUp Health - the innovation network that named Ambrosia a "Health Transformer" - calls low-resource settings. Diabetes care in a rural clinic is a different engineering problem than diabetes care in downtown San Francisco, and designing for the clinic forced a discipline on every product decision: what can we remove, and what can we make cheaper?

Those figures are the company's own, and worth treating as directional rather than audited. But the direction is the whole point. When a founder tells you the hard part is affordability, and then ships a decade of cheaper products, the strategy is not a slogan - it is the roadmap.

03 / The new betRIZZ, and the honesty play

In July 2025 Ambrosia launched RIZZ, a titanium smart ring that pre-ordered at $249 and reads far more than sugar. It tracks glucose trends, sleep stages, stress, heart rate, HRV, blood oxygen, and skin temperature, with a five-to-seven day battery and no subscription required for the core ring functions. For people who want true clinical-grade CGM, the ring pairs with the BluCon add-on.

Here is the part that stands out. Non-invasive glucose sensing is the holy grail of wearables, and the graveyard is full of companies that claimed to have cracked it. RIZZ doesn't. It uses optical sensors to estimate the direction your glucose is moving - pre-meal baseline, post-meal spike, overnight stability - and it says so plainly. Independent reviewers have noted the ring "openly admits its accuracy limitations" and is "unsuitable for clinical decisions." In a category built on overpromising, that candor reads as a feature, not a flaw.

04 / How it's differentThe metric nobody else leads with

The smart-ring aisle is crowded - Oura, Ultrahuman, Samsung's Galaxy Ring, and a wall of clones. Almost all of them lead with sleep and recovery, and treat metabolic data as an afterthought or skip it entirely. On the CGM side, programs like Levels and Nutrisense do glucose properly but rely on the very sensors and patches Ambrosia is trying to make optional. RIZZ plants a flag in the gap between them.

	RIZZ	Typical smart ring	CGM program
Glucose trends	Yes (estimated)	No	Yes (sensor)
Needle-free	Yes	Yes	No
Sleep / stress / HRV	Yes	Yes	Rarely
Clinical-grade option	Add-on BluCon	No	Built in

It is a positioning choice more than a technology claim: take the metric the incumbents bury, make it the headline, and price it for the people they ignore. Whether the optical glucose estimates prove useful enough over time is the open question - the brand has, by reviewers' own count, only a couple of years of track record behind it.

05 / The businessHardware, subscriptions, and other people's clinics

Ambrosia sells three ways. First, direct-to-consumer hardware: the BluCon and now RIZZ, checked out through a WooCommerce and Stripe storefront. Second, recurring CGM service bundles - one, three, and twelve-month packages that combine Libre sensors, a waterproof transmitter, smart patches, and app access, sold in most countries outside the United States. Third, a white-label platform pitched to clinics and partners with "zero startup cost," letting other organizations launch diabetes and weight-management programs on Ambrosia's stack.

The customers span the full range of the condition: people with pre-diabetes and Type 1, Type 2, and gestational diabetes, plus the caregivers and parents watching over them, and a growing set of metabolic-health and fitness users who never had a diagnosis at all. All of it runs on a team of around 32 people - small for a company shipping regulated-adjacent hardware into more than 100 markets.

One honest caveat the company itself flags: its apps are not FDA approved and are not meant for making medical decisions. RIZZ gives you trends and nudges, not a prescription. Read the tool for what it is and it earns its place; expect a lab result on your finger and you will be disappointed.

That is the copyable lesson buried in Ambrosia's decade. The company was named, fittingly, after ambrosia - the food of the Greek gods, the stuff that was supposed to make you live forever. The real product is more modest and more useful: a running read on your own body, priced so the number of people who can afford it keeps going up.